Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURVENT: Furmonertinib vs platinum-based chemotherapy in first-line EGFR exon 20 insertion NSCLC
jRCT2011230009Phase 3Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression-free survival (PFS). Started Aug 2023; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2011230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230009.